Literature DB >> 3690187

Intravesical BCG therapy in the management of multiple superficial bladder carcinoma. Comparison between Glaxo and Pasteur strains.

A V Kaisary1.   

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) therapy in the treatment and prophylaxis of superficial bladder cancer has shown encouraging results in North America but disappointing results have been reported in Great Britain. This was attributed to differences in quality between BCG (Glaxo strain) used in Great Britain and BCG (Pasteur and Tice strains) used in North America. Twenty-one patients with multiple superficial recurrent transitional cell carcinoma of the bladder were entered into a pilot study comparing the efficacy of BCG Glaxo (Evans Medical Ltd, Dunstable, UK) and Pasteur (L'Institut Pasteur, France) strains. Comparable and encouraging results were demonstrated, indicating that this mode of therapy is effective.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3690187     DOI： 10.1111/j.1464-410x.1987.tb04876.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


  5 in total

Review 1.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

2.  The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.

Authors:  J Alfred Witjes; Guido Dalbagni; Robert J Karnes; Shahrokh Shariat; Steven Joniau; Joan Palou; Vincenzo Serretta; Stéphane Larré; Savino di Stasi; Renzo Colombo; Marek Babjuk; Per-Uno Malmström; Nuria Malats; Jacques Irani; Jack Baniel; Tommaso Cai; Eugene Cha; Peter Ardelt; John Varkarakis; Riccardo Bartoletti; Martin Spahn; Francesca Pisano; Paolo Gontero; Richard Sylvester
Journal:  Urol Oncol       Date:  2016-09-14       Impact factor: 3.498

3.  Iatrogenic prostatic granulomata.

Authors:  P Ramani; M Griffin
Journal:  J Clin Pathol       Date:  1988-09       Impact factor: 3.411

Review 4.  BCG in the treatment of superficial cancer of the bladder: a review.

Authors:  S Friberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

5.  Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.

Authors:  Eila C Skinner; Ettore De Berardinis; Francesco Del Giudice; Gian Maria Busetto; Martin S Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I Chung; Simon L Conti; Michael L Eisenberg
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-06       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.